Dasatinib and quercetin prevent alveolar bone loss in aged mice
Aging increases the risk of periodontitis due to immune decline, chronic inflammation, and the accumulation of senescent cells, which release inflammatory factors that damage tissues. Senolytic drugs, such as dasatinib and quercetin (D&Q), selectively eliminate senescent cells and have shown promise in age-related diseases. In this study, we tested whether D&Q could reduce alveolar bone loss associated with aging or experimental periodontitis. The D&Q treatment protected aged mice by reducing bone loss, but it failed to prevent bone loss in the periodontitis model. These results suggest that the benefits of senolytic therapy may depend on disease context and treatment conditions.
Authors
- Ana Lia Anbinder (ORCID: https://orcid.org/0000-0003-3930-4274)
- Renata Falchete do Prado (ORCID: https://orcid.org/0000-0001-5970-0464)
- Jaqueline Lemes Ribeiro (ORCID: https://orcid.org/0000-0002-6398-7880)
- Renata Mendonça Moraes (ORCID: https://orcid.org/0000-0002-4484-5932)
- Florent Elefteriou (ORCID: https://orcid.org/0000-0002-2972-5633)
- Maíra Terra Garcia (ORCID: https://orcid.org/0000-0002-1193-2909)
- Luisa Souza Battistelli
- Yuri Cavalcanti Santos
Institutions
- St. Jude Children's Research Hospital (US)
- Baylor College of Medicine (US)
- Department of Aerospace Science and Technology (BR)
Publication Details
- Journal
- Journal of Periodontology
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1002/jper.70115
- Primary Topic
- Telomeres, Telomerase, and Senescence
- Type
- article
- Field-Weighted Citation Impact
- 0.00